Close menu

July 21st, 2023 | 07:20 CEST

BioNxt Solutions, Morphosys, Palantir - Innovative therapies for Parkinson's, cancer and soaring with AI

  • Biotechnology
  • Pharma
  • Cancer
  • AI
  • Technology
Photo credits:

There are exciting developments in the biotech industry. Thanks to innovative AI technologies, companies like BioNxt Solutions can analyze medical data faster and develop an innovative medical patch that provides Parkinson's patients with faster symptom relief. This patch carries the active ingredient rotigotine and has enormous market opportunities worldwide. Blockbuster-level market opportunities are emerging at Morphosys with regard to its compound pelabresib for the treatment of a rare form of blood cancer. The Phase III trial is expected to deliver results earlier than expected, and analysts see promising opportunities for the drug. According to a study by Bristol Myers Squibb, about 1.85 million new cases of blood cancer are expected worldwide in 2040. Deutsche Bank rated the stock "hold," driving the price up 4.9% this week. Also pushing upward is Palantir. The US company is getting into the drone business thanks to a partnership with Canada's Airmatrix.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: Bionxt Solutions Inc. | CA0909741062 , MORPHOSYS AG O.N. | DE0006632003 , PALANTIR TECHNOLOGIES INC | US69608A1088

Table of contents:

    Sébastien Plouffe, CEO, Defence Therapeutics Inc.
    "[...] Orano had already experimented with Accum™ prior to working with us and then decided to collaborate. [...]" Sébastien Plouffe, CEO, Defence Therapeutics Inc.

    Full interview


    BioNxt Solutions: Develops innovative approach to alleviating Parkinson's disease

    There is a lot going on in the biotech sector right now. Investors know that medical research, in particular, requires staying power. Thanks to innovative AI technologies, companies are already able to analyze and evaluate data faster and more efficiently. BioNxt Solutions is developing an innovative medical patch which will enable Parkinson's patients to enjoy symptom relief more quickly. What many readers overlook is that the skin is our largest organ, and active substances absorbed through the skin reach the bloodstream faster than any pill.

    Parkinson's disease often manifests as uncontrollable trembling of one hand and stiffness of the body. As it progresses, other symptoms may include slurred speech, a sluggish gait, loss of the sense of smell, and dementia. Men are 50% more likely to develop PD than women, and in most cases, symptoms appear at age 60 or older.

    The drug for the current standard of care for Parkinson's was discovered 66 years ago. To date, Parkinson's cannot be cured; only its symptoms can be alleviated. Reason enough for BioNxt Solutions to do valuable pioneering work in this area.

    The patch carries the active ingredient rotigotine, which is approved for treating Parkinson's disease and restless legs syndrome (RLS) in Europe and the US. As a patch, it is applied once daily to ensure controlled, consistent drug delivery over 24 hours. According to Wissen Market Research, total global sales of rotigotine patches were approximately EUR 462.7 million in 2021, and the market is expected to exceed EUR 684.3 million by 2030.

    Morphosys: On track for blockbuster drug in the fight against cancer

    The German-American biotech company Morphosys is confident about its drug Pelabresib for the treatment of a rare form of blood cancer. Blood cancers arise in blood-forming tissues such as bone marrow or immune system cells. Leukaemia, lymphoma and multiple myeloma are examples of blood cancers. Company CEO Jean-Paul Kress expressed optimism to the "Frankfurter Allgemeine Zeitung" and is convinced that blockbuster status can be achieved with this. In the pharmaceutical industry, blockbuster drugs are those that generate sales of more than USD 1 billion (EUR 893 million) per year. Results from the Phase III trial are expected at the end of this year, six months ahead of schedule because patients were recruited more quickly.

    According to a study by Bristol Myers Squibb, approximately 1.85 million new blood cancer cases are expected worldwide in 2040. Lymphoma accounts for 918,872 cases, leukaemia 656,345 cases, and myeloma 275,047 cases. The study also predicts approximately 1,100,000 deaths worldwide due to blood cancers by 2040. Morphosys' therapeutic agent targets the cancer condition Myelofibrosis.

    Myelofibrosis is a disease in which blood-forming cells in the bone marrow are overgrown by connective tissue, resulting in abnormally shaped red blood cells, anaemia and an enlarged spleen. This disease can occur independently, through certain gene mutations, or due to other blood disorders. Morphosys is conducting research on Pelabresib (CPI-0610). It is a development-stage compound. It aims to promote anti-tumor activity by inhibiting the function of certain proteins to reduce the outgrowth of abnormally expressed genes in cancer.

    Deutsche Bank analysts rated the stock a "hold. " In his research note, analyst Emmanuel Papadakis highlighted the importance of myelofibrosis to the European pharmaceutical industry and the opportunities for Morphosys' drug Pelabresib, which is currently in a pivotal trial phase against the malignant bone marrow disease. Data on this is expected in the fourth quarter. Traders rewarded that assessment, sending the stock soaring 4.9% this week.

    Palantir: Enters drone technology in Canadian airspace

    Palantir Technologies and Canadian company AirMatrix, a pioneer in airspace infrastructure technology, have announced a strategic partnership to accelerate and scale drone operations by leveraging Palantir Foundry through the Foundry for Builders Program. AirMatrix is harnessing the potential of urban aviation and working on technology that will enable autonomous commercial drone operations worldwide.

    AirMatrix's main products are "Palladium UTM" and Libra. Palladium UTM is designed specifically for corporate drone pilots and fleet managers. It enables them to apply for airspace permits, manage their fleet, and focus entirely on flying. Libra is a sophisticated airspace management platform enabling civil authorities to scale and manage drone traffic effectively. At the same time, it provides the opportunity to generate revenue as commercial drones take to the skies.

    AirMatrix joins several other Canadian companies working with Palantir - from energy to financial services to manufacturing. As part of the Foundry for Builders Program, AirMatrix has begun enhancing its two commercial drone software products, Libra and Palladium.

    "Drone technology is increasingly being used not only for beneficial applications but also for nefarious or illegal purposes," said David MacNaughton, Director & Head of Palantir Technologies Canada. "Palantir Canada is pleased to support AirMatrix in accelerating and scaling our business and securing our airspace with local technical expertise."

    For investors, it is good to know that Palantir results for Q2/23, which ended June 30, 2023, will be released on Monday, August 7, 2023, after the close of the US market.

    Life-threatening diseases require innovative research and technologies to give sufferers back the quality of life they deserve. BioNxt Solutions, a promising biotech company, is stepping up to shake up the Parkinson's therapy market after 66 years of stagnation. With their innovative patch, patients benefit from rapid drug absorption through the skin in a growing market. According to Research and Markets, the global transdermal skin patch market was worth nearly USD 6.5 billion in 2020, while Kuick Research, Pharmaceutical and Healthcare, estimates the market will reach about USD 20 billion by 2028. Morphosys, for its part, is focused on fighting blood cancer and has a blockbuster-level drug candidate in the pipeline. The future drug is designed to inhibit tumor growth. Initial research results make the CEO optimistic. In the future, Canadian airspace will also become safer thanks to Palantir and the company AirMatrix. Both are working hand in hand on drone technology for surveillance.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.


    Commented by André Will-Laudien on September 28th, 2023 | 08:05 CEST

    Attention: Extended correction - Buy the right stocks now! Bayer, Viva Gold, TUI, and BASF are on the list!

    • Mining
    • Gold
    • Pharma
    • chemicals
    • travel

    Higher inflation and rising interest rates - this connection should be clear to investors. The interest rate level in Germany has moved from negative territory to 2.77% in the 10-year range, but stocks continued to rise cheerfully. The party led to all-time highs of 16,528 points in July, but the fundamental situation of the companies deteriorated in parallel. Only after repeated warnings from the US Federal Reserve did the explosive NASDAQ also enter a correction. And it continues. Yesterday, the CEO of US investment bank JPMorgan, Dimon, warned that the world may not be prepared for 7% capital market interest rates. He and Dr. Jens Erhardt, the CEO of the asset management company DJE, warn of stronger setbacks on the stock markets. Some stocks have already undergone a strong correction. Here is a brief overview.


    Commented by Stefan Feulner on September 27th, 2023 | 08:30 CEST

    AI shares in focus:, Norcom, Amazon - Upgrade at any cost

    • Software
    • AI
    • Technology

    The implementation of generative artificial intelligence on a large scale has the potential to significantly boost the German economy, according to a study by IW Consult, conducted on behalf of Google. In this context, the comprehensive integration of programs such as ChatGPT by at least half of domestic companies could increase economic output by around EUR 330 billion. This value corresponds to almost 10% of the German gross domestic product of the previous year. This is likely to herald a quantum leap for providers of intelligent software.